Researchers at Oregon Health & Science University report that combining the BCL2 inhibitor venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia activity in AML models than venetoclax alone. The Cell Reports Medicine paper analyzed over 300 patient samples and validated effects in human tissues and mouse xenografts, finding the combo co‑targets cell‑cycle and protein‑synthesis pathways to overcome common resistance mechanisms. Investigators highlight the combination as a preclinical candidate to address near‑universal venetoclax resistance in AML and call for clinical evaluation.